Scarica l'app Stockscreener
485.65
0.08%
-0.38
Pre-mercato:
487.70
2.05
+0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$486.03
Aprire:
$483.51
Volume 24 ore:
1.57M
Relative Volume:
1.06
Capitalizzazione di mercato:
$123.26B
Reddito:
$12.34B
Utile/perdita netta:
$4.34B
Rapporto P/E:
28.79
EPS:
16.8685
Flusso di cassa netto:
$3.71B
1 W Prestazione:
+0.05%
1M Prestazione:
+5.81%
6M Prestazione:
+10.03%
1 anno Prestazione:
+4.83%
Intervallo 1D:
$481.98
$496.69
Intervallo di 1 settimana:
$469.60
$496.69
Portata 52W:
$362.50
$533.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2 - Yahoo Finance Singapore
Vertex Pharmaceuticals just made a $10 billion acquisition worth watching - MSN
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching - The Motley Fool
Latigo preps IPO to fund non-opioid rival to Vertex’s Journax - Fierce Biotech
Vertex Pharma stock steadies as cystic fibrosis franchise drives revenue and investors watch next da - ad-hoc-news.de
5 Best Biotech Stocks for 2026 and How to Invest - The Motley Fool
Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics - Genetic Engineering and Biotechnology News
Vertex Pharma stock trades near record highs as cystic fibrosis franchise drives earnings momentum - Ad Hoc News
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Lobbying Update: $1,200,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout | AI
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharma stock steadies as analysts watch cystic fibrosis - ad-hoc-news.de
Vertex Pharmaceuticals (Ondo Tokenized) price today, VRTXON to USD live price, marketcap and chart - CoinDesk
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021 -- Data Talk - Moomoo
Vertex Pharmaceuticals Stock 6-Day Losing Spree: Stock Falls 10% - Trefis
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal - Yahoo Finance
Vertex Pharmaceuticals Stock Slides 10% Over 6 Straight Down Days - Trefis
Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Calamos Advisors LLC - InsuranceNewsNet
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals - The Motley Fool
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - The Motley Fool
VRTX Maintained by UBS -- Price Target Raised to $585 - GuruFocus
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - The Motley Fool
UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating - Moomoo
VRTX Maintained by Truist Securities -- Price Target Raised to $560 - GuruFocus
What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report - Yahoo Finance
Truist raises Vertex stock price target to $560 on Crinetics deal - Investing.com
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550 - Moomoo
Vertex Pharma stock holds steady as cystic fibrosis franchise underpins long-term growth outlook - ad-hoc-news.de
Drugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offerings - Post and Courier
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crin - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crinetics Pharmaceuticals - GuruFocus
The week in pharma: action, reaction and insight – week to July 10, 2026 - The Pharma Letter
Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada - Yahoo Finance
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse - TradingView
Biotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tape - TechStock²
Is This Biotech Stock a Buy Near Its 52-Week High? - The Motley Fool
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal - Stock Titan
Why This Pharmaceutical Stock Jumped Close to 100% This Week - Yahoo Finance
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal - RTTNews
Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’ - Sahm
Rx Rundown: Vertex Pharmaceuticals, Real Chemistry, Vera Therapeutics and more - Medical Marketing and Media
A $10B deal, China trial scrutiny and highlights from ADA 2026 - Fierce Pharma
If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vertex Pharmaceuticals Inc Azioni (VRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
0.33%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):